GABRB3 encephalopathy OMIM 617113

In GABRB3 encephalopathy OMIM 617113 (GABRB3, OMIM 617113), the master switch sits on the ↓ DOWN branch ([F] forced below); the healthy state is the ON well. The forced corrective direction is to raise s toward ON branch (polarity: supply). Classification: ✓ Recovers an existing standard. Direction only — no dose, no efficacy magnitude.

The disease maps to an R19 double-well whose corrective lever is read straight off the cusp (barrier 0.4963, γ 1.4090, spinodal 0.6437). The corrective direction is forced [F]; the agent names below are direction-concordant labels at grade [O] (no dose, no efficacy or safety magnitude). This is a research hypothesis offered to experts, not medical advice.

The emergence switch

The switch for GABRB3 encephalopathy OMIM 617113 is an R19 double-well emerged from the real proximal-promoter DNA of GABRB3. Its geometry is fixed by measured stiffness γ (never fitted); the numbers below are read directly off that cusp.

emergent axis
↓ DOWN [F]
healthy branch
ON
lesion
LOF_null
γ (stiffness)
1.4090
barrier
0.4963
spinodal
0.6437
s_on / s_off
1.1870 / -1.1870
fragility
0.47
corrective polarity
supply
forced direction
raise s toward ON branch

Chemistry feasibility (DIRECTION only [O]). small-molecule recrossing of the fold is geometrically plausible (barrier 0.4963 at neutral drive; lower barrier = smaller drive to supply). [O] -- no affinity/potency/dose/efficacy asserted.

The derived corrective lever

The cusp forces a corrective direction: raise s toward ON branch. This is the load-bearing output of the framework — it is [F] forced, and it is falsifiable. 2 lever families are derived; the lead is h-restore (drive modulator).

h-restore (drive modulator)sign: increasegeometric rank 0.47
Mechanism. supply / restore the positive drive (replace-or-agonise the missing competence)
Applies to. allele-agnostic (downstream/environmental tilt)
favoured when the switch is fragile -- a small drive shift recrosses the fold
Falsifier. If supplying/agonising deficient GABA-A inhibitory tone from the GABRB3 beta3-subunit defect (raising the switch drive) does NOT move the DOWN [F] switch toward the healthy branch in a GABRB3-deficient model, the h-restore(supply) lever is refuted for this axis.
gamma-restore (stabiliser / chaperone)sign: Nonegeometric rank 0.00
Mechanism. N/A
Applies to. none (honest exclusion)
EXCLUDED: null allele -- no product to stiffen
Falsifier. If a folding-stabiliser/chaperone does NOT re-deepen the healthy well for a residual GABRB3 allele (no rescue that a null allele lacks), the gamma-restore lever is refuted; null alleles are excluded by construction.

Agents mapped onto the lever

Existing agents whose known action is direction-concordant with the derived lever (status as pinned in the corpus; no dose, no efficacy magnitude).
agent (class)dir.statusphasemap
GABA-A receptor agonism (benzodiazepine) augmenting the deficient GABAergic inhibition
Tanaka 2008 Am J Hum Genet 82:1249
increasesymptomatic standard (not disease-modifying)0—
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.

Direction-only candidate leads (corpus join)

Each lead is surfaced only because its known mechanism points the same way as the derived lever, and each comes with a source and a falsifier. None is a treatment.

GABA-A receptor agonism (benzodiazepine) [GABRB3 encephalopathy]✓ recovered standarddir: increase · symptomatic standard (not disease-modifying)
Class. GABA-A receptor positive modulator (inhibitory-tone augmentation)
Mechanism. Direction-concordant (increase) agent for GABRB3; magnitude open [O]; direction-only repurposing/recovery signal, not a claim of efficacy or safety for any patient.
✓ This is a rediscovery. GABA-A agonism (benzodiazepines) augments the deficient inhibition and is a symptomatic standard in GABRB3 epilepsy (direction-concordant; symptomatic, not disease-modifying).
Safety (qualitative; no magnitude). established/known-use safety reporting on record (qualitative; no magnitude)
Falsifier. If GABA-A receptor agonism (benzodiazepine) [GABRB3 encephalopathy] (a gene-specific supply/increase agent) does NOT move the DOWN [F] switch toward the healthy branch in a GABRB3-deficient model, the h-restore(supply) direction is refuted for GABA-A receptor agonism (benzodiazepine) [GABRB3 encephalopathy] here.
Source: Tanaka 2008 Am J Hum Genet 82:1249 (reduced GABA currents of mutant GABRB3)
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.

Evidence & provenance

What is reproduced vs. cited for this page.
elementgradebasis
R19 switch & cusp geometry (this page)[V] verifiedemerged from measured promoter γ of GABRB3; deterministic, 2×sha256 identical
corrective direction[F] forcedforced by the cusp sign; falsifiable (see lever falsifiers)
mapped agents / leads[O] opendirection-concordance only; corpus-pinned (2026-06-21); no dose, no efficacy/safety magnitude

Reading the agent column. VALIDATION SIGNAL -- the agent is already approved / established standard for this disease, so the direction logic recovered known clinical practice. Not a new claim by this kit. GENUINE HYPOTHESIS -- no approved indication for this disease; the direction match is a direction-only, untested [O] lead. Basis field grades the evidence (investigational here / in a related condition / off-label / speculative).